1021 related articles for article (PubMed ID: 9195290)
1. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
2. Development of matrix metalloproteinase inhibitors in cancer therapy.
Hidalgo M; Eckhardt SG
J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
Rasmussen HS; McCann PP
Pharmacol Ther; 1997; 75(1):69-75. PubMed ID: 9364582
[TBL] [Abstract][Full Text] [Related]
4. Batimastat. BB 94, collagenase inhibitors-1.
Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
[No Abstract] [Full Text] [Related]
5. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase inhibitors: a novel class of anticancer agents.
Brown PD
Adv Enzyme Regul; 1995; 35():293-301. PubMed ID: 7572350
[TBL] [Abstract][Full Text] [Related]
7. [Recent progress of matrix metalloproteinase (MMP) research and its clinical application for cancer therapy].
Otani Y; Fujii M; Kubota T; Kitajima M; Okada Y
Gan To Kagaku Ryoho; 1998 Jun; 25(7):957-64. PubMed ID: 9644306
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.
Chavey C; Mari B; Monthouel MN; Bonnafous S; Anglard P; Van Obberghen E; Tartare-Deckert S
J Biol Chem; 2003 Apr; 278(14):11888-96. PubMed ID: 12529376
[TBL] [Abstract][Full Text] [Related]
9. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
10. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis.
Goss KJ; Brown PD; Matrisian LM
Int J Cancer; 1998 Nov; 78(5):629-35. PubMed ID: 9808534
[TBL] [Abstract][Full Text] [Related]
11. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
12. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.
Tonn JC; Kerkau S; Hanke A; Bouterfa H; Mueller JG; Wagner S; Vince GH; Roosen K
Int J Cancer; 1999 Mar; 80(5):764-72. PubMed ID: 10048980
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase inhibitors: present achievements and future prospects.
Denis LJ; Verweij J
Invest New Drugs; 1997; 15(3):175-85. PubMed ID: 9387040
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
Taraboletti G; Garofalo A; Belotti D; Drudis T; Borsotti P; Scanziani E; Brown PD; Giavazzi R
J Natl Cancer Inst; 1995 Feb; 87(4):293-8. PubMed ID: 7535861
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases. Novel targets for directed cancer therapy.
Yu AE; Hewitt RE; Connor EW; Stetler-Stevenson WG
Drugs Aging; 1997 Sep; 11(3):229-44. PubMed ID: 9303281
[TBL] [Abstract][Full Text] [Related]
16. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
[TBL] [Abstract][Full Text] [Related]
17. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix.
Collen A; Hanemaaijer R; Lupu F; Quax PH; van Lent N; Grimbergen J; Peters E; Koolwijk P; van Hinsbergh VW
Blood; 2003 Mar; 101(5):1810-7. PubMed ID: 12393408
[TBL] [Abstract][Full Text] [Related]
18. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
Prontera C; Mariani B; Rossi C; Poggi A; Rotilio D
Int J Cancer; 1999 May; 81(5):761-6. PubMed ID: 10328230
[TBL] [Abstract][Full Text] [Related]
20. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
Furukawa A; Tsuji M; Nishitani M; Kanda K; Inoue Y; Kanayama H; Kagawa S
Urology; 1998 May; 51(5):849-53. PubMed ID: 9610608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
